Selentus and CuraMedrix are pleased to report their first clinical publication for TenaTac®, a novel bioresorbable and adhesive haemostat. TenaTac reduces the risk of post-operative bleeding and deploys a patented surface modification that replaces blood derived ingredients present in current products.  See the publication at  https://lnkd.in/eHEiSfmn